Compare Matson Inc (MATX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Matson Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Matson Inc trades at $214.74 (market cap $6.11B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Matson Inc pays a 0.74% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| MATX | XBI | |
|---|---|---|
Market Cap | $6.11B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $223.55 | $164.28 |
52-Week Low | $88.05 | $86.92 |
Enterprise Value | $6.71B | — |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Matson (MATX) trades at $214.45, up 2.76% with strong earnings momentum after beating Q2 2026 EPS estimates of $3.79 with $4.27 actual. The stock shows bullish technical signals with support at $200 and resistance at $209. Fundamentally, the company maintains solid profitability with 13.41% net margin and 17.21% ROE, supported by raised full-year guidance after strong Q2 results.
MATX presents a compelling investment case with 27.3% upside to consensus price target of $265, supported by 66.7% analyst buy ratings. Key risks include exposure to Trans-Pacific trade volatility and competitive shipping markets, but resilient consumer demand and premium China service position the company for continued growth.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
